Relevant randomized clinical trials comparing transplant with standard treatment in NDMM patients aged up to 70 years
| Study . | Starting year . | Number of randomized patients . | Induction . | Transplant regimen . | Standard regimen . | Survival benefit of transplant . |
|---|---|---|---|---|---|---|
| IFM9010 | 1990 | 200 | VMCP/VBAP | Mel 140/TBI-8 | VMCP/VBAP | EFS + OS |
| MAG9011 | 1990 | 185 | VAMP | Cc/Cy/VP/Mel 140/TBI-12 | VMCP | EFS |
| MAG9114 | 1991 | 190 | VAMP | Bu/Mel 140 or Mel 200 | VMCP | EFS |
| MRC712 | 1993 | 401 | VAMPC | Mel 200 or Mel 140/TBI | ABCM | PFS + OS |
| S932116 | 1993 | 516 | VAD | Mel 140/TBI-12 | VBMCP | None |
| PETHEMA15 | 1994 | 164 | VBMCP/VBAD | Mel 200 or Mel 140/TBI-12 | VBMCP/VBAD | None |
| M97G13 | 1997 | 194 | VAD | Mel 100 × 2 | MP | EFS + OS |
| IFM200917,18 | 2010 | 700 | VRD ( × 3) | Mel 200 | VRD ( × 5) | PFS |
| DETERMINATION19 | 2010 | 722 | VRD ( × 3) | Mel 200 | VRD ( × 5) | PFS + EFS |
| EMN02/HO9520 | 2011 | 1197 | VCD ( × 3 or 4) | Mel 200 ( × 1 or × 2) | VMP | PFS + PFS2 + OS |
| FORTE21 | 2015 | 474 | KRD or KCD ( × 4) | Mel 200 | KRD ( × 8) | PFS |
| EMN CARTITUDE623 | 2024 | 750 planned | DVRD ( × 4) | Mel 200 | cilta-cel | ? |
| Study . | Starting year . | Number of randomized patients . | Induction . | Transplant regimen . | Standard regimen . | Survival benefit of transplant . |
|---|---|---|---|---|---|---|
| IFM9010 | 1990 | 200 | VMCP/VBAP | Mel 140/TBI-8 | VMCP/VBAP | EFS + OS |
| MAG9011 | 1990 | 185 | VAMP | Cc/Cy/VP/Mel 140/TBI-12 | VMCP | EFS |
| MAG9114 | 1991 | 190 | VAMP | Bu/Mel 140 or Mel 200 | VMCP | EFS |
| MRC712 | 1993 | 401 | VAMPC | Mel 200 or Mel 140/TBI | ABCM | PFS + OS |
| S932116 | 1993 | 516 | VAD | Mel 140/TBI-12 | VBMCP | None |
| PETHEMA15 | 1994 | 164 | VBMCP/VBAD | Mel 200 or Mel 140/TBI-12 | VBMCP/VBAD | None |
| M97G13 | 1997 | 194 | VAD | Mel 100 × 2 | MP | EFS + OS |
| IFM200917,18 | 2010 | 700 | VRD ( × 3) | Mel 200 | VRD ( × 5) | PFS |
| DETERMINATION19 | 2010 | 722 | VRD ( × 3) | Mel 200 | VRD ( × 5) | PFS + EFS |
| EMN02/HO9520 | 2011 | 1197 | VCD ( × 3 or 4) | Mel 200 ( × 1 or × 2) | VMP | PFS + PFS2 + OS |
| FORTE21 | 2015 | 474 | KRD or KCD ( × 4) | Mel 200 | KRD ( × 8) | PFS |
| EMN CARTITUDE623 | 2024 | 750 planned | DVRD ( × 4) | Mel 200 | cilta-cel | ? |
ABCM, doxorubicin-carmustine-cyclophosphamide-melphalan; CC, lomustine; cilta-cel, ciltacabtagene-autoleucel; Cy, cyclophosphamide; DVRD, daratumumab-bortezomib-lenalidomide-dexamethasone; VAD, vincristine-doxorubicin-dexamethasone; VAMP, vincristine-doxorubicin- methylprednisolone; VAMPC, vincristine-doxorubicin-methylprednisolone-cyclophosphamide; VBAD, vincristine-carmustine-doxorubicin- dexamethasone; VBAP, vincristine-carmustine-doxorubicin-prednisone; VCD, bortezomib-cyclophosphamide-dexamethasone; VMCP, vincristine- melphalan-cyclophosphamide-prednisone; VMP, bortezomib-melphalan-dexamethasone; VP, etoposide; VRD, bortezomib-lenalidomide-dexamethasone.